Short Interest in Bionano Genomics, Inc. (NASDAQ:BNGO) Expands By 26.4%

by · The Cerbat Gem

Bionano Genomics, Inc. (NASDAQ:BNGO – Get Free Report) saw a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 7,670,000 shares, a growth of 26.4% from the September 30th total of 6,070,000 shares. Based on an average trading volume of 1,820,000 shares, the days-to-cover ratio is currently 4.2 days. Currently, 9.0% of the company’s shares are sold short.

Bionano Genomics Stock Down 2.6 %

Shares of NASDAQ:BNGO traded down $0.01 during trading hours on Wednesday, hitting $0.31. The company’s stock had a trading volume of 127,121 shares, compared to its average volume of 1,645,054. The firm’s fifty day moving average price is $0.42 and its 200 day moving average price is $0.64. Bionano Genomics has a 52 week low of $0.28 and a 52 week high of $2.27. The company has a market capitalization of $20.40 million, a price-to-earnings ratio of -0.05 and a beta of 2.32. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.63 and a quick ratio of 1.11.

Bionano Genomics (NASDAQ:BNGO – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.24) EPS for the quarter. Bionano Genomics had a negative return on equity of 151.27% and a negative net margin of 557.98%. The company had revenue of $7.77 million during the quarter. As a group, research analysts expect that Bionano Genomics will post -1.42 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on BNGO shares. BTIG Research downgraded shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Tuesday, September 10th. Scotiabank reaffirmed a “sector perform” rating and set a $1.00 target price (down from $6.00) on shares of Bionano Genomics in a research report on Wednesday, August 28th.

View Our Latest Analysis on BNGO

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in shares of Bionano Genomics during the first quarter valued at about $36,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Bionano Genomics by 123.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock worth $79,000 after buying an additional 38,900 shares during the period. Carret Asset Management LLC grew its holdings in shares of Bionano Genomics by 89.0% during the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after buying an additional 40,055 shares during the last quarter. Cetera Advisors LLC acquired a new stake in Bionano Genomics during the 1st quarter worth about $163,000. Finally, GSA Capital Partners LLP grew its stake in Bionano Genomics by 532.7% during the 1st quarter. GSA Capital Partners LLP now owns 549,789 shares of the company’s stock valued at $610,000 after purchasing an additional 462,887 shares during the last quarter. Hedge funds and other institutional investors own 11.35% of the company’s stock.

Bionano Genomics Company Profile

(Get Free Report)

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.

Featured Articles